"Teladoc Health's stock has gained 1.37% over the past week and 3.83% over the past month, yet remains down 21.21% year-to-date and nearly 36% over the past year."
"Barclays recently cut its price target on Teladoc to $7 from $8.50, maintaining an Equal Weight rating, while acknowledging pockets of optimism in the business."
"BetterHelp revenue fell 7% year-over-year in Q4 2025, with guidance for 2026 indicating a further decline as the segment shifts toward insurance-based delivery."
"International revenue surged 19% year-over-year to $125 million in Q4 2025, representing nearly 24% of total segment revenue for full-year 2025."
Teladoc Health's stock has increased slightly in the short term but is down significantly year-to-date and over the past year. The stock is far below its 52-week high and has experienced a dramatic five-year decline. Analysts are cautious, with a consensus target price indicating potential upside. Barclays has reduced its price target but acknowledges some optimism in specific business areas. Key drivers for stock performance include BetterHelp's insurance scaling, international revenue growth, and improving profitability metrics.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]